GlassScriptPhysician profile
Madhav Srivastava
NPI 1770565905
$4,347.26
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,974 · 2020: $1,087 · 2021: $938 · 2022: $332 · 2023: $16.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $543.60 | 2019-2020 | |
| Genzyme Corporation | $421.19 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $377.92 | 2019-2021 | |
| Biogen, INC. | $374.18 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $288.48 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $287.09 | 2020-2021 | |
| Emd Serono, INC. | $205.54 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $171.32 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $152.67 | 2021-2022 | |
| Genentech USA, INC. | $141.34 | 2019-2023 | Ocrevus, Enspryng |
| Vanda Pharmaceuticals INC. | $101.95 | 2019-2020 | |
| Mdd US Operations, LLC | $100.33 | 2020-2021 | |
| Catalyst Pharmaceuticals, INC. | $96.62 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $91.53 | 2019-2022 | |
| Abbvie INC. | $91.20 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $88.83 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.00 | 2019 | |
| Amgen INC. | $62.21 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $61.05 | 2019-2021 | |
| Lundbeck LLC | $56.30 | 2019 | |
| Allergan, INC. | $53.68 | 2019-2020 | |
| Acorda Therapeutics, INC | $52.44 | 2019 | |
| Lilly USA, LLC | $48.95 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $48.87 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $44.90 | 2019 | |
| Neurocrine Biosciences, INC. | $43.20 | 2020-2021 | |
| Genentech, INC. | $39.95 | 2019 | |
| Jazz Pharmaceuticals INC. | $32.92 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $23.49 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.70 | 2022 | |
| Horizon Therapeutics Plc | $22.58 | 2022 | |
| Eisai INC. | $18.89 | 2021 | |
| Banner Life Sciences, LLC | $18.64 | 2021 | |
| Alnylam Pharmaceuticals INC. | $16.29 | 2022 | |
| Bausch Health US, LLC | $15.70 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.50 | 2021 | |
| Greenwich Biosciences, INC. | $14.59 | 2019 | |
| Neurelis, INC. | $13.16 | 2020 | |
| Sk Life Science, INC. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhav Srivastava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.